Case Study

Improving Enrollment For Challenging Protocol

iStock-1292777578-autoinjector-injector-device-patient

A biopharma company developed an ingestible powder composed of non-digestible oligosaccharides specifically for patients with ulcerative colitis (UC), with a goal of positively affecting their gut microbiomes. The study needed to enroll 30 subjects with mild to moderate UC symptoms both domestically and abroad. Elligo was brought on to assist with enrolling 20 subjects in the U.S. 

Find out the challenges and solutions in the available case study.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Hydrocarbon Online? Subscribe today.

Subscribe to Hydrocarbon Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Hydrocarbon Online